These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 28980030)
1. [Hyponatremia in a 58-year-old female patient with EGFR-positive lung adenocarcinoma]. Koch M; Utpatel K; Schulz C Internist (Berl); 2018 Apr; 59(4):384-387. PubMed ID: 28980030 [TBL] [Abstract][Full Text] [Related]
2. Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication. Wang XF; Zhao QT; Chen C Am J Ther; 2020; 27(5):e535-e537. PubMed ID: 31567148 [No Abstract] [Full Text] [Related]
3. Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing "wax-and-wane" transformation. Takagi Y; Nakahara Y; Hosomi Y; Hishima T BMC Cancer; 2013 Nov; 13():529. PubMed ID: 24195468 [TBL] [Abstract][Full Text] [Related]
4. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature. Shi Y; Wang M Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401 [TBL] [Abstract][Full Text] [Related]
5. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911 [TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib. Ikeuchi T; Tokuyasu H; Ishikawa S Intern Med; 2019; 58(1):101-104. PubMed ID: 30606938 [TBL] [Abstract][Full Text] [Related]
8. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation? Wahab A; Kesari K; Chaudhary S; Khan M; Khan H; Smith S; Boumber Y Cancer Biol Ther; 2017 Dec; 18(12):940-943. PubMed ID: 29157085 [TBL] [Abstract][Full Text] [Related]
9. Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report. Jiang Y; Shou L; Guo Q; Bao Y; Xu X; An S; Lu J Medicine (Baltimore); 2021 Aug; 100(32):e26911. PubMed ID: 34397927 [TBL] [Abstract][Full Text] [Related]
10. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells. Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation. Tanaka M; Ishii H; Moribuchi H; Naito Y; Matsuo N; Nakamura M; Tokito T; Azuma K; Yamada K; Hoshino T Invest New Drugs; 2018 Aug; 36(4):715-717. PubMed ID: 29546681 [TBL] [Abstract][Full Text] [Related]
12. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib. Ibrahim U; Saqib A; Atallah JP Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646 [TBL] [Abstract][Full Text] [Related]
13. Afatinib-Induced Tumor Lysis Syndrome in Pulmonary Adenocarcinoma: A Case Report and Literature Review. Hong G Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138247 [TBL] [Abstract][Full Text] [Related]
14. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma? Zhang Y; Li XY; Tang Y; Xu Y; Guo WH; Li YC; Liu XK; Huang CY; Wang YS; Wei YQ Lung Cancer; 2013 Aug; 81(2):302-5. PubMed ID: 23683536 [TBL] [Abstract][Full Text] [Related]
15. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma. Zeng L; Zhang Y; Yang N J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651 [No Abstract] [Full Text] [Related]
16. Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis. Lin CH; Lin MT; Kuo YW; Ho CC Lung Cancer; 2014 Sep; 85(3):479-80. PubMed ID: 24999085 [TBL] [Abstract][Full Text] [Related]
17. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220 [TBL] [Abstract][Full Text] [Related]
18. Lung carcinoma with diffuse cystic lesions misdiagnosed as pulmonary langerhans cell histocytosis: a case report. Gui X; Ding J; Li Y; Yu M; Chen T; Huang M; Xiao Y BMC Pulm Med; 2020 Feb; 20(1):30. PubMed ID: 32019517 [TBL] [Abstract][Full Text] [Related]
19. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410 [TBL] [Abstract][Full Text] [Related]
20. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis. Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]